Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences is experiencing robust growth driven by increasing demand and market share gains, particularly with its HIV drug Biktarvy, which holds 52% of the U.S. market share and is projected to generate an additional $500 million in sales by 2026. The company has raised its growth guidance for HIV to +5% year-over-year, despite anticipated challenges from Medicare Part D, indicating confidence in its market position and product pipeline. Furthermore, Gilead's strategic initiatives in oncology, alongside positive outcomes from early programs, suggest a diversified growth trajectory that enhances its overall financial outlook.

Gilead Sciences has experienced notable revenue declines, including a 60% year-over-year drop in Veklury sales to $277 million, which fell short of expectations and prompted a reduction in FY25 revenue guidance. Additionally, the company's cell therapy sector, which has seen a 10% anticipated decline in revenue for 2025, reported an 11% year-over-year reduction, totaling $432 million and significantly underperforming consensus estimates. Trodelvy sales also declined slightly quarter-over-quarter, suggesting broader challenges within Gilead's portfolio that could hamper future growth prospects.